Q2 2021 13F Holders as of 6/30/2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
125M
-
Number of holders
-
200
-
Total 13F shares, excl. options
-
64.6M
-
Shares change
-
-210K
-
Total reported value, excl. options
-
$4.08B
-
Value change
-
+$9.8M
-
Put/Call ratio
-
0.86
-
Number of buys
-
117
-
Number of sells
-
-76
-
Price
-
$63.20
Significant Holders of Apellis Pharmaceuticals, Inc. - Common Stock (APLS) as of Q2 2021
247 filings reported holding APLS - Apellis Pharmaceuticals, Inc. - Common Stock as of Q2 2021.
Apellis Pharmaceuticals, Inc. - Common Stock (APLS) has 200 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 64.6M shares
of 125M outstanding shares and own 51.6% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (10.7M shares), VANGUARD GROUP INC (6.34M shares), BlackRock Inc. (5.67M shares), PRICE T ROWE ASSOCIATES INC /MD/ (5.17M shares), HHLR ADVISORS, LTD. (2.93M shares), JENNISON ASSOCIATES LLC (2.45M shares), BAKER BROS. ADVISORS LP (2.27M shares), STATE STREET CORP (1.95M shares), VICTORY CAPITAL MANAGEMENT INC (1.66M shares), and Farallon Capital Management LLC (1.55M shares).
This table shows the top 200 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.